← All trials
NCT07276360
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 3, 2026
- Primary completion
- Jan 2, 2028
- Completion date
- Jan 2, 2029
- First posted
- Dec 11, 2025
- Last posted
- Dec 11, 2025
- Enrollment
- 278
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Uganda Cancer InstituteLead sponsor
- National Institutes of Health (NIH)Collaborator
- Uganda Cancer InstituteOfficial
- Varian Medical SystemsCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.